BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pölzl G, Allipour Birgani S, Comín-Colet J, Delgado JF, Fedele F, García-Gonzáles MJ, Gustafsson F, Masip J, Papp Z, Störk S, Ulmer H, Vrtovec B, Wikström G, Altenberger J. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail 2019;6:174-81. [PMID: 30378288 DOI: 10.1002/ehf2.12366] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Pollesello P. Facing up to the challenges of acute heart failure. Eur Heart J Suppl 2020;22:D1-2. [PMID: 32431567 DOI: 10.1093/eurheartj/suaa089] [Reference Citation Analysis]
2 Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F, Metra M. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 2022. [PMID: 35352499 DOI: 10.1002/ehf2.13859] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cholley B, Caruba T. Should we keep levosimendan in our pharmacies? Yes, undoubtedly! Anaesth Crit Care Pain Med 2019;38:211-2. [PMID: 31076141 DOI: 10.1016/j.accpm.2019.04.007] [Reference Citation Analysis]
4 Manito Lorite N, Rubio-Rodríguez D, González Costello J, Díez López C, Enjuanes Grau C, Segovia-Cubero J, Delgado Jimenez JF, Campo Sien C, Rubio-Terrés C, Comín-Colet J; LION-HEART study researchers., Additional researchers in the LION-HEART Group. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain. Rev Esp Cardiol (Engl Ed) 2020;73:361-7. [PMID: 31899185 DOI: 10.1016/j.rec.2019.06.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Iacovoni A, D'Elia E, Gori M, Oliva F, Lorini FL, Senni M. Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. Card Fail Rev 2019;5:78-82. [PMID: 31179016 DOI: 10.15420/cfr.2018.46.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Grześk G, Wołowiec Ł, Rogowicz D, Gilewski W, Kowalkowska M, Banach J, Hertmanowski W, Dobosiewicz M. The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan. Biomedicine & Pharmacotherapy 2022;153:113391. [DOI: 10.1016/j.biopha.2022.113391] [Reference Citation Analysis]
7 Liang B, Zhao YX, Zhang XX, Liao HL, Gu N. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol 2020;19:55. [PMID: 32375806 DOI: 10.1186/s12933-020-01024-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Häberle HA. [Levosimendan - a 20-Year Experience]. Anasthesiol Intensivmed Notfallmed Schmerzther 2021;56:414-26. [PMID: 34187074 DOI: 10.1055/a-1214-4485] [Reference Citation Analysis]
9 Masarone D, Melillo E, Gravino R, Errigo V, Martucci ML, Caiazzo A, Petraio A, Pölzl G, Pacileo G. Inotropes in Patients with Advanced Heart Failure: Not Only Palliative Care. Heart Fail Clin 2021;17:587-98. [PMID: 34511207 DOI: 10.1016/j.hfc.2021.05.004] [Reference Citation Analysis]
10 Tycińska A, Gierlotka M, Bartuś S, Gąsior M, Główczyńska R, Grześk G, Jaguszewski M, Kasprzak JD, Kubica J, Legutko J, Leszek P, Nessler J, Pacileo G, Ponikowski P, Sobkowicz B, Stępińska J, Straburzyńska-Migaj E, Wojakowski W, Zawiślak B, Zymliński R; LEIA-HF Investigators. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Adv Med Sci 2022;67:18-22. [PMID: 34656873 DOI: 10.1016/j.advms.2021.10.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Manito Lorite N, Rubio-rodríguez D, González Costello J, Díez López C, Enjuanes Grau C, Segovia-cubero J, Delgado Jimenez JF, Campo Sien C, Rubio-terrés C, Comín-colet J, Pinilla JMG, Almenar L, Crespo-leiro MG, Sionis A, Blasco T, Pascual-figal D, Gonzalez-vilchez F, Lambert-rodríguez JL, Grau M. Análisis económico del tratamiento ambulatorio intermitente con levosimendán de la insuficiencia cardiaca avanzada en España. Revista Española de Cardiología 2020;73:361-7. [DOI: 10.1016/j.recesp.2019.06.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
12 Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LMA, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, Papp JG, Parissis J, Parkhomenko A, Põder P, Pölzl G, Reinecke A, Ricksten SE, Riha H, Rudiger A, Sarapohja T, Schwinger RHG, Toller W, Tritapepe L, Tschöpe C, Wikström G, Lewinski DV, Vrtovec B, Pollesello P. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. J Cardiovasc Pharmacol 2020;76:4-22. [PMID: 32639325 DOI: 10.1097/FJC.0000000000000859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Pollesello P, Ben Gal T, Bettex D, Cerny V, Comin-Colet J, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Harjola VP, Herpain A, Heringlake M, Heunks L, Husebye T, Ivancan V, Karason K, Kaul S, Kubica J, Mebazaa A, Mølgaard H, Parissis J, Parkhomenko A, Põder P, Pölzl G, Vrtovec B, Yilmaz MB, Papp Z. Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline? J Clin Med 2019;8:E1834. [PMID: 31683969 DOI: 10.3390/jcm8111834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Elsherbini H, Soliman O, Zijderhand C, Lenzen M, Hoeks SE, Kaddoura R, Izham M, Alkhulaifi A, Omar AS, Caliskan K. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients. Heart Fail Rev 2021. [PMID: 33839989 DOI: 10.1007/s10741-021-10101-0] [Reference Citation Analysis]
15 Anker MS, Papp Z, Földes G, von Haehling S. ESC Heart Failure increases its impact factor. ESC Heart Fail 2020. [PMID: 33118326 DOI: 10.1002/ehf2.13069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Brida M, Lovrić D, Griselli M, Gil FR, Gatzoulis MA. Heart failure in adults with congenital heart disease. International Journal of Cardiology 2022. [DOI: 10.1016/j.ijcard.2022.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Conti N, Gatti M, Raschi E, Diemberger I, Potena L. Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Des Devel Ther 2021;15:3391-409. [PMID: 34376973 DOI: 10.2147/DDDT.S295214] [Reference Citation Analysis]
18 Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, Tomasoni D. A year in heart failure: an update of recent findings. ESC Heart Fail 2021;8:4370-93. [PMID: 34918477 DOI: 10.1002/ehf2.13760] [Reference Citation Analysis]
19 Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LM, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, Papp JG, Parissis J, Parkhomenko A, Põder P, Pölzl G, Reinecke A, Ricksten SE, Riha H, Rudiger A, Sarapohja T, Schwinger RH, Toller W, Tritapepe L, Tschöpe C, Wikström G, von Lewinski D, Vrtovec B, Pollesello P. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Card Fail Rev 2020;6:e19. [PMID: 32714567 DOI: 10.15420/cfr.2020.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Vishram-Nielsen JKK, Tomasoni D, Gustafsson F, Metra M. Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs 2022. [PMID: 35113350 DOI: 10.1007/s40265-021-01666-z] [Reference Citation Analysis]
21 Farmakis D, Agostoni P, Baholli L, Bautin A, Comin-Colet J, Crespo-Leiro MG, Fedele F, García-Pinilla JM, Giannakoulas G, Grigioni F, Gruchała M, Gustafsson F, Harjola VP, Hasin T, Herpain A, Iliodromitis EK, Karason K, Kivikko M, Liaudet L, Ljubas-Maček J, Marini M, Masip J, Mebazaa A, Nikolaou M, Ostadal P, Põder P, Pollesello P, Polyzogopoulou E, Pölzl G, Tschope C, Varpula M, von Lewinski D, Vrtovec B, Yilmaz MB, Zima E, Parissis J. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. Int J Cardiol 2019;297:83-90. [PMID: 31615650 DOI: 10.1016/j.ijcard.2019.09.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
22 Lebedeva NB, Chesnokova LY. The Use of Levosimendan for the Treatment of Heart Failure and its Potential Organoprotective Effects. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;18:218-24. [DOI: 10.20996/1819-6446-2022-04-12] [Reference Citation Analysis]
23 Pölzl G, Allipour Birgani S, Comín-Colet J, Delgado JF, Fedele F, García-Gonzáles MJ, Gustafsson F, Masip J, Papp Z, Störk S, Ulmer H, Vrtovec B, Wikström G, Altenberger J. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail 2019;6:174-81. [PMID: 30378288 DOI: 10.1002/ehf2.12366] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
24 Masarone D, Pacileo G. Repeated infusion of levosimendan in outpatients with advanced heart failure: to cure sometimes, to relieve often, and to comfort always. J Cardiovasc Med (Hagerstown) 2021;22:150. [PMID: 32858644 DOI: 10.2459/JCM.0000000000001100] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Herpain A, Bouchez S, Girardis M, Guarracino F, Knotzer J, Levy B, Liebregts T, Pollesello P, Ricksten SE, Riha H, Rudiger A, Sangalli F. Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper. J Cardiovasc Pharmacol 2019;73:3-14. [PMID: 30489437 DOI: 10.1097/FJC.0000000000000636] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]